Investigating the immune effects of carbon ion radiation therapy for pancreatic cancer
Official title: Relative Immunological Effectiveness (RIE) of Carbon Ion Radiation Therapy for Pancreatic Cancer
Funded at Albert Einstein College of Medicine · NIH-11005715 · Data updated 2026-11-12
This study is looking at how a special type of radiation therapy called carbon ion radiation therapy might help boost the immune system to fight pancreatic cancer better than regular X-ray therapy, and it's being tested in mice to see if it could lead to new treatment options for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | January 14, 2021 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $412,656 |
| NIH project number | 5R01CA257509-05 |
| Project ID | NIH-11005715 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic cancer who are seeking innovative treatment options.
✕Less likely to help
Patients with non-cancerous conditions or those who are not diagnosed with pancreatic cancer may not benefit from this research.
What this research studies
This research explores how carbon ion radiation therapy (CIRT) can enhance the immune response against pancreatic cancer. By comparing CIRT to traditional X-ray radiation therapy, the study aims to understand how CIRT's unique properties can lead to better tumor control and potentially improve patient outcomes. The research involves testing these therapies in a mouse model to evaluate their effectiveness in stimulating the immune system to fight cancer. If successful, this approach could lead to new treatment options for patients with pancreatic cancer.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that enhances the immune response against pancreatic cancer, potentially improving survival rates.
How similar studies have gone: While carbon ion therapy is a relatively novel approach, previous studies with proton therapy have shown promising results in enhancing tumor control and immune response.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Guha, Chandan — Albert Einstein College of Medicine
- Study coordinator: Guha, Chandan
Related research
Other NIH-funded projects on the same topics.
-
Targeting tumor survival signals to improve radiation response in pancreatic cancer
This grant tests a new approach to make pancreatic cancer tumors more sensitive to radiation, aiming to help patients with locally advanced disease become eligible for surgery or experience better disease control.
-
Using minibeam radiation to improve delivery of cancer-fighting nanoparticles to pancreatic tumors
This study is exploring a new way to help deliver tiny cancer-fighting particles directly to pancreatic tumors using a special type of radiation therapy, which could make treatments more effective and safer for patients like you.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.